Novartis Presents 10 Cardiovascular Abstracts at ESC 2026, Including Phase IV Inclisiran and Abelacimab Data

Novartis's expanding cardiovascular biologics portfolio, spanning RNA-based therapies, monoclonal antibodies, and established small molecules, arrives at the 2026 European Society of Cardiology (ESC) Congress with ten accepted abstracts, a volume that signals sustained pipeline pressure on manufacturing scale-up and analytical method development at both in-house and contract facilities.

The highest-profile data package centers on Leqvio (inclisiran), the siRNA-based LDL-C lowering agent, with late-breaking Phase IV results from the VICTORION-CHALLENGE trial comparing inclisiran head-to-head against bempedoic acid in high- and very-high-cardiovascular-risk patients. A second Leqvio abstract from the VICTORION-Difference trial presents exploratory findings on whether an inclisiran-based strategy reduces the need for therapy escalation to reach LDL-C targets. For facilities already handling oligonucleotide drug substance or formulation, the Phase IV readout carries direct relevance: commercial demand projections for inclisiran will track closely with these outcomes.

Abelacimab, an investigational factor XI monoclonal antibody, contributes an AZALEA-TIMI 71 analysis examining total and recurrent bleeding events versus rivaroxaban in atrial fibrillation patients. The bleeding-profile characterization is a regulatory prerequisite for any future BLA or MAA submission, and the granularity of recurrent-event data will inform risk-benefit labeling discussions. Facilities preparing for potential abelacimab scale-up should note that factor XI-targeted mAbs require upstream process controls distinct from those governing conventional IgG platforms.

Pacibekitug, an IL-6 ligand monoclonal antibody in development for chronic kidney disease with high cardiovascular risk, appears in the Hot Line session with TRANQUILITY trial data on monthly and quarterly dosing. Extended-interval biologics introduce specific stability and container-closure considerations under 21 CFR Part 211 and ICH Q1 shelf-life guidance; QA leads at CDMOs evaluating this asset class should factor those requirements into technology-transfer timelines.

The Lp(a)CCELERATE initiative, conducted in partnership with the European Atherosclerosis Society, presents implementation strategies for Lp(a) testing across European clinical practice, a signal that Novartis is building diagnostic infrastructure ahead of anticipated Lp(a)-targeting therapies entering late-stage development. Entresto (sacubitril/valsartan) rounds out the portfolio with PARACHUTE-HF data in Chagas disease-related heart failure, extending the established product's evidence base into an underserved indication.

The VICTORION-CHALLENGE Phase IV readout on August 31 will be the clearest near-term indicator of inclisiran's competitive positioning and, by extension, the manufacturing demand trajectory for GMP-compliant siRNA production at scale.

Source: Novartis via GlobeNewswire, August 19, 2026.